EPO requirements for description amendments challenged

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

EPO requirements for description amendments challenged

Sponsored by

inspicos-400px recrop.jpg
copenhagen-1721511.jpg

The European Patent Office (EPO)’s requirement for the description of a patent to confirm the claims at the final stage of grant or opposition proceedings is coming under attack, as Jakob Pade Frederiksen of Inspicos explains

A peculiarity of EPO practice is that the description is usually required to be brought into conformity with the claims at the final stage of grant or opposition proceedings.

According to the EPO Guidelines, part F-IV 4.3: “Any inconsistency between the description and the claims must be avoided if it could throw doubt on the subject-matter for which protection is sought.”

If the description includes embodiments not covered by the scope of the claims, amendment of the description is required by deleting those embodiments or marking them as not falling within the scope of the claims.

The Guidelines refer to Article 84 EPC, which stipulates that the claims shall be clear and concise and be supported by the description, as the legal basis for the requirement.

Rules 42(1)(c) and 48(1)(c) EPC have in some contexts been cited as a legal basis for requirements for description amendments; according to these provisions the description shall disclose the invention as claimed in such terms that the technical problem and its solution can be understood, and the description shall not contain any statement or other matter obviously irrelevant or unnecessary.

In two recent decisions, two chemical Boards of Appeal of the EPO have questioned to what extent a sound legal basis exists for these description requirements.

Recent decisions raise doubts

In T 1989/18 of 21 December 2021, it was held that, if the claims are clear in themselves and supported by the description, their clarity is not affected if the description contains subject-matter that is not claimed.

A subsequent decision, T 1444/20 of 28 April 2022, held that there is no requirement for the applicant to delete claim-like clauses or redundant subject-matter from the claims.

However, a number of other recent decisions, including decisions T 121/20, T 1024/18, T 2766/17 and T 2293/18 (all of which have emerged from non-chemical cases), maintain that adaptation of the description to the claims is a requirement under the provisions of the EPC.

Many patent practitioners hope that the current seemingly contradictory lines of case law will eventually provide a basis for an Enlarged Board of Appeal referral that could make a clean sweep.

more from across site and SHARED ros bottom lb

More from across our site

The firm reveals how its litigation strategies informed the arguments that took Masimo’s judgment past $818 million
The firm was rebuilding its IP practice through a string of patent hires and a Texas expansion, but its dissolution has put the newly built talent back into the market
AI can exploit longstanding gaps in copyright protection at remarkable speed, but EU law still provides tools to fight back, says Simon Hembt at Bird & Bird
The firm has tapped a local patent trio to establish a foothold in the market and broaden its national presence
New Asia-Pacific IP head Jonathan Chu is eyeing opportunities arising from Chinese technology licensing, overseas enforcement and increasingly IP-heavy cross-border deals
Europe’s largest intellectual property convention and trade fair is back: IP Service World 2026 takes place in Munich from November 23–25 – the 16th edition, with 1,400-plus attendees from 55-plus nations, 100-plus speakers, and 100-plus exhibitors. Three days. Two focused areas. One IP marketplace.
Mehmet Gün and Uğur Aktekin discuss four decades of change in Türkiye’s legal market, the firm’s commitment to independence and the challenge of building an institution that can outlast its founders
Boehringer Ingelheim has instructed a team from Kirkland, while Teva is being represented by Pinsent Masons
The Delhi High Court’s latest directions offer an opportunity to move beyond remedies against bad-faith registrations and address how suspicious applications are identified in the first place, says Fatima Baig at Lexlinc
Camilla Hamrin describes how the acquisition by Acapo Onsagers will impact Bergenstråhle’s trademark practice – and reflects on changes she has seen over 30 years in IP
Gift this article